Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood product could cut transfusions in major surgeries

NCT ID NCT05711524

Completed Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a pathogen-reduced version of cryoprecipitate, a blood product that helps blood clot, in 208 patients undergoing liver transplant or heart surgery. The goal was to see if having this product readily available could stop bleeding early and reduce the need for other blood transfusions. Researchers compared it to the standard cryoprecipitate already in use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pathogen-reduced cryoprecipitate (fibrinogen concentrate)
What this could lead to
If it works, this could make a safer, more readily available blood product to control bleeding during major surgeries, reducing the need for other transfusions.
What could go wrong
This is a small pilot study, so results may not apply broadly. The pathogen-reduced product may not work as well as the standard one, and any blood product carries risks like allergic reactions or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED FIBRINOGEN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired coagulation factor deficiency congenital afibrinogenemia familial hypofibrinogenemia Hemorrhage hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLEEDING HYPOFIBRINOGENEMIA

Contacts and locations

Locations

  • New York-Presbyterian Hospital/Weill Cornell Medical Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.